innosferaНаука и инновацииScience and Innovations1818-98572412-9372Издательский дом «Белорусская наука»innosfera-1060Research ArticleТЕМА НОМЕРА: ТЕХНОЛОГИИ СУВЕРЕНИТЕТАТЕМА НОМЕРА: ТЕХНОЛОГИИ СУВЕРЕНИТЕТАCAR-T-терапия: сегодня и завтраCAR-T therapy: today and tomorrowДорошенкоТатьянаDoroshenkoTatyana

Татьяна Дорошенко, заведующий отделением клеточных технологий Республиканской молекулярно-генетической лаборатории канцерогенеза, кандидат биологических наук, доцент,

Минск.

ДормешкинДмитрийDormeshkinDmitry

Дмитрий Дормешкин, ведущий научный сотрудник лаборатории молекулярной диагностики биотехнологий, кандидат химических наук, доцент,

Минск.

КрасныйСергейKrasnySergey

Сергей Красный, заместитель директора по научной работе, доктор медицинских наук, академик,

Минск.

РНПЦ онкологии и медицинской радиологии им. Н.Н. АлександроваBelarusИнститут биоорганической химии НАН БеларусиBelarus202621072026062833Copyright © Издательский дом «Белорусская наука», 20262026Издательский дом «Белорусская наука»Издательский дом «Белорусская наука»https://innosfera.belnauka.by/jour/about/submissions#copyrightNoticehttps://innosfera.belnauka.by/jour/article/view/1060

Показаны возможности CAR T-терапии – генно-инженерного клеточного метода, который стал прорывом в лечении онкологических заболеваний, а также достижения белорусских ученых в этой передовой области.

The article analyzes the potential of CAR-T therapy – a genetically engineered cell method that has become a breakthrough in cancer treatment, and highlights the achievements of Belarusian scientists in this cutting-edge field.

ReferencesCAR-T cell therapy for cancer: current challenges and future directions / I. Zugasti, L. Espinosa-Aroca, K. Fidyt // Signal Transduct Target Ther. 2025. Jul №4 10(1) Р. 210. https://doi.org/10.1038/s41392-025-02269-w/.CAR-T cell therapy for cancer: current challenges and future directions / I. Zugasti, L. Espinosa-Aroca, K. Fidyt // Signal Transduct Target Ther. 2025. Jul №4 10(1) Р. 210. https://doi.org/10.1038/s41392-025-02269-w/.Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived c regions / Y. Kuwana, Y. Asakura, N. Utsunomiya [et al.] // Biochem Biophys Res C o m m u n . 19 87. №149. Р. 9 6 0 – 9 6 8 . https://doi.org/10.1016/0006-291X(87)90502-X.Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived c regions / Y. Kuwana, Y. Asakura, N. Utsunomiya [et al.] // Biochem Biophys Res C o m m u n . 19 87. №149. Р. 9 6 0 – 9 6 8 . https://doi.org/10.1016/0006-291X(87)90502-X.Gross G. Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity / G. Gross, T. Waks, Z. Eshhar // Proc Natl Acad Sci U.S.A. 1989. №86. Р. 10024–10028. https://doi.org/10.1073/pnas.86.24.10024.Gross G. Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity / G. Gross, T. Waks, Z. Eshhar // Proc Natl Acad Sci U.S.A. 1989. №86. Р. 10024–10028. https://doi.org/10.1073/pnas.86.24.10024.From bench to bedside: the history and progress of CAR T cell therapy / A. Mitra, A. Barua, L. Huang [et al.] // Front Immunol. 2023. №15. Р. 1188049. https://doi.org/10.3389/fimmu.2023.1188049.From bench to bedside: the history and progress of CAR T cell therapy / A. Mitra, A. Barua, L. Huang [et al.] // Front Immunol. 2023. №15. Р. 1188049. https://doi.org/10.3389/fimmu.2023.1188049.T Current updates on generations, approvals, and clinical trials of CAR T-cell therapy / Asmamaw Dejenie, G. Tiruneh M. Medhin [et al.] // Hum Vaccin Immunother. 2022. №18(6). Р. 2114254. https://doi.org/10.1080/21645515.2022.2114254.T Current updates on generations, approvals, and clinical trials of CAR T-cell therapy / Asmamaw Dejenie, G. Tiruneh M. Medhin [et al.] // Hum Vaccin Immunother. 2022. №18(6). Р. 2114254. https://doi.org/10.1080/21645515.2022.2114254.CAR-T cell manufacturing: Major process parameters and next-generation strategies / M. Ayala Ceja, M. Khericha, C. M. Harris [et al.] // J Exp Med. 2024. №221(2). Р. e20230903. https://doi.org/10.1084/jem.20230903.CAR-T cell manufacturing: Major process parameters and next-generation strategies / M. Ayala Ceja, M. Khericha, C. M. Harris [et al.] // J Exp Med. 2024. №221(2). Р. e20230903. https://doi.org/10.1084/jem.20230903.Sterner R.C. CAR-T cell therapy: current limitations and potential strategies / R. C Sterner, R. M. Sterner // Blood Cancer J. 2021. №11(4). Р. 69. https://doi.org/10.1038/s41408-021-00459-7.Sterner R.C. CAR-T cell therapy: current limitations and potential strategies / R. C Sterner, R. M. Sterner // Blood Cancer J. 2021. №11(4). Р. 69. https://doi.org/10.1038/s41408-021-00459-7.Alsaieedi A.A. Tracing the development of CAR-T cell design: from concept to next-generation platforms / A.A. Alsaieedi, K.A. Zaher // Front. Immunol. 2025. №16. Р. 1615212. https://doi.org/10.3389/fimmu.2025.1615212.Alsaieedi A.A. Tracing the development of CAR-T cell design: from concept to next-generation platforms / A.A. Alsaieedi, K.A. Zaher // Front. Immunol. 2025. №16. Р. 1615212. https://doi.org/10.3389/fimmu.2025.1615212.The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies / E.R. Pennings, F.W. Thielen, F. Broussais [et al.] // Hemasphere. 2026. №10(3). Р. e70306. https://doi.org/10.1002/hem3.70306.The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies / E.R. Pennings, F.W. Thielen, F. Broussais [et al.] // Hemasphere. 2026. №10(3). Р. e70306. https://doi.org/10.1002/hem3.70306.Hill J.A. CAR-T – and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR-T cell therapy / J.A. Hill, S. Giralt, T.R. Torgerson, H.M. Lazarus // Blood Rev. 2019. №38. Р. 100596. https://doi.org/10.1016/j.blre.2019.100596.Hill J.A. CAR-T – and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR-T cell therapy / J.A. Hill, S. Giralt, T.R. Torgerson, H.M. Lazarus // Blood Rev. 2019. №38. Р. 100596. https://doi.org/10.1016/j.blre.2019.100596.Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma / X. Deschênes-Simard, M. Bromberg, S.M. Devlin [et al.] // Blood Adv. 2025. №9 (21). Р. 5571–5584.Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma / X. Deschênes-Simard, M. Bromberg, S.M. Devlin [et al.] // Blood Adv. 2025. №9 (21). Р. 5571–5584.Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies / Y. Zhao, D. Zhang, Y. Guo [et al.] // Front. Oncol. 2021. №11. Р. 680834. https://doi.org/10.3389/fonc.2021.680834.Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies / Y. Zhao, D. Zhang, Y. Guo [et al.] // Front. Oncol. 2021. №11. Р. 680834. https://doi.org/10.3389/fonc.2021.680834.Rebagay G. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy / G. Rebagay, S. Yan, C. Liu and N.K. Cheung // Front. Oncol. 2012. №2. Р. 34. https://doi.org/10.3389/fonc.2012.00034.Rebagay G. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy / G. Rebagay, S. Yan, C. Liu and N.K. Cheung // Front. Oncol. 2012. №2. Р. 34. https://doi.org/10.3389/fonc.2012.00034.Therapeutic advances in the targeting of ROR1 in hematological cancers / A.B. Tigu, R. Munteanu, C. Moldovan [et al.] // Cell Death Discov. 2024. №10(1). Р. 471. https://doi.org/10.1038/s41420-024-02239-1.Therapeutic advances in the targeting of ROR1 in hematological cancers / A.B. Tigu, R. Munteanu, C. Moldovan [et al.] // Cell Death Discov. 2024. №10(1). Р. 471. https://doi.org/10.1038/s41420-024-02239-1.Lin W. IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis / W. Lin, R. Niu, S.M. Park [et al.] // Nat Commun. 2023. №14(1). Р. 1578. https://doi.org/10.1038/s41467-023-37306-1.Lin W. IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis / W. Lin, R. Niu, S.M. Park [et al.] // Nat Commun. 2023. №14(1). Р. 1578. https://doi.org/10.1038/s41467-023-37306-1 .Zhu H. ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells / H. Zhu, L. Cheng, D. Liu [et al.] // Neuro Oncol. 2025. № 27(3). Р. 695–710. https://doi.org/10.1093/neuonc/noae224.Zhu H. ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells / H. Zhu, L. Cheng, D. Liu [et al.] // Neuro Oncol. 2025. № 27(3). Р. 695–710. https://doi.org/10.1093/neuonc/noae224.Jung M.S. The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling / M.S. Jung, W.Y. Choi, W. Zhang [et al.] // Int J Mol Sci. 2025. №26(16). Р. 7828. https://doi.org/10.3390/ijms2667828 . PMID : 40869147; PMCID : PMC12386924.Jung M.S. The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling / M.S. Jung, W.Y. Choi, W. Zhang [et al.] // Int J Mol Sci. 2025. №26(16). Р. 7828. https://doi.org/10.3390/ijms2667828 . PMID : 40869147; PMCID : PMC12386924.Faust J.R. Mesothelin: An Immunotherapeutic Target beyond Solid Tumors / J.R Faust., D. Hamill, E.A. Kolb [et al.] // Cancers. 2022. №14. Р. 1550. https://doi.org/10.3390/cancers14061550.Faust J.R. Mesothelin: An Immunotherapeutic Target beyond Solid Tumors / J.R Faust., D. Hamill, E.A. Kolb [et al.] // Cancers. 2022. №14. Р. 1550. https://doi.org/10.3390/cancers14061550.Boisgard R. Mesothelin biology and the evolving landscape of targeted immunotherapy / R. Boisgard, P. Chames, B. Kerfelec //Molecular Therapy Oncology. 2026. №34. Р. 1–6Boisgard R. Mesothelin biology and the evolving landscape of targeted immunotherapy / R. Boisgard, P. Chames, B. Kerfelec //Molecular Therapy Oncology. 2026. №34. Р. 1–6

The authors declare that there are no conflicts of interest present.